Pfizer and BioNTech’s coronavirus vaccine candidate, BNT162b2, which relies on mRNA (messenger RNA) to teach the immune system to produce antibodies that target the virus, is enrolling participants in a clinical trial in Honolulu, Hawaii. At present, fewer than 20% of participants have experienced side effects. When it comes to clinical trials world and nation-wide, Yourway provides the full scope of our client’s biopharmaceutical storage and distribution needs; outsourcing to a single global provider optimizes supply chain efficiency and minimizes risk.